Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 189 matching trials from the live ClinicalTrials.gov search.
Conditions
Premature Rupture of Membrane, Unfavorable Cervix
Interventions
Intracervical balloon catheter, Oxytocin
Device · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Rezafungin

NCT04117607
Conditions
Fungal Infection
Interventions
Placebo, Rezafungin
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Conditions
AL Amyloidosis
Interventions
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Cleveland, Ohio
Conditions
Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, Fludarabine, mycophenolate mofetil, umbilical cord blood transplantation, total body irradiation, Sirolimus
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Alpha1-antitrypsin Deficiency
Interventions
GLASSIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more
Conditions
Type 1 Diabetes
Interventions
Autologous UCB, Omega 3 FA, Vitamin D
Biological · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
Interventions
Paclitaxel Protein Bound (Abraxane)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Conditions
Leukemia-Lymphoma, Adult T-Cell
Interventions
Bortezomib, Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide, Raltegravir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Conditions
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
Drug · Radiation · Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Conditions
Lymphoma
Interventions
rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve System, furosemide infusion
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Irvine, California • Long Beach, California • Sacramento, California + 28 more
Conditions
Anesthesia, Intravenous Fluid, Blood Pressure
Interventions
Lung Recruitment Maneuver, Fluid Administration
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 17 Years
Enrollment
48 participants
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Infiltration, Extravasation, IV Infiltration, IV Extravasation, Extravasation of Diagnostic and Therapeutic Materials
Interventions
Not listed
Lead sponsor
ivWatch, LLC
Industry
Eligibility
Up to 12 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Conditions
Fluid Loss, Symptom Complex, Triple, Emergencies
Interventions
Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag
Drug
Lead sponsor
Nicholas M Mohr
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trial of Intravenous Fluids During Labor

NCT01110005
Conditions
Ketosis
Interventions
D5 Lactated Ringer's Solution (D5LR), Lactated Ringer's Solution (LR)
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Female only
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Allentown, Pennsylvania • Bethlehem, Pennsylvania • Hershey, Pennsylvania + 1 more
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
REGN2477, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
Conditions
Oxytocin, Pregnancy
Interventions
Oxytocin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Tetralogy of Fallot
Interventions
Cardiac Magnetic Resonance Imaging (CMRI), Central venous line placement, Chest X-ray, Fluid administration, Blood Draw, Pregnancy test, Electrocardiogram
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
gemcitabine hydrochloride, floxuridine, proteomic profiling, matrix-assisted laser desorption/ionization time of flight mass spectrometry, liquid chromatography, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, laboratory biomarker analysis, mass spectrometry, pharmacological study
Drug · Genetic · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Duarte, California